SCHEMBL1673176

SCHEMBL1673176

C[Si](C)(C)CCOCn1c(=O)n(C2CCN(C(=O)N[C@@H]3CC[C@@H](c4cccc(F)c4F)[C@H](NC(=O)O)c4cccnc43)CC2)c2cccnc21

nearest known ligand 0.45

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CALCRL Q16602 20/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1673182 1.00 CALCRL (0.45) CALCRL
SCHEMBL13740257 0.96 CALCRL (0.44) CALCRL
SCHEMBL13740258 0.96 CALCRL (0.44) CALCRL
SCHEMBL12206967 0.92 CALCRL (0.43) CALCRL
SCHEMBL2520422 0.88 CALCRL (0.44) CALCRL
SCHEMBL13832607 0.88 CALCRL (0.42) CALCRL
SCHEMBL829061 0.87 CALCRL (0.51) CALCRL
SCHEMBL828554 0.87 CALCRL (0.51) CALCRL
SCHEMBL13741228 0.80 CALCRL (0.43) CALCRL
SCHEMBL13741226 0.80 CALCRL (0.43) CALCRL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488512-B1 CGRP receptor antagonists BRISTOL MYERS SQUIBB CO (US) 2013-11-27 EP disclosed
US-20130053570-A1 CGRP Receptor Antagonists BRISTOL MYERS SQUIBB CO (US) 2013-02-28 US disclosed
US-8314117-B2 CGRP receptor antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2012-11-20 US disclosed
EP-2488512-A1 CGRP RECEPTOR ANTAGONISTS Bristol-Myers Squibb Company (US) 2012-08-22 EP disclosed
WO-2011046997-A1 CGRP RECEPTOR ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053570-A1 CGRP Receptor Antagonists CALCRL, BDKRB2, CALCR CALCRL 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.